Author Interviews, Cancer Research, Prostate Cancer / 01.10.2020

MedicalResearch.com Interview with: Maha Hussain, MD, FACP, FASCO Genevieve Teuton Professor of MedicineDivision of Hem/Onc Deputy Director Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine MedicalResearch.com: What is the background for this study? Response: PROfound is an open-label international Phase III clinical trial which evaluated the efficacy and safety of Olaparib (Lynparza) versus enzalumatide or abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior treatment with NHA treatments (abiraterone and prednisone or enzalutamide) and have a qualifying tumor mutation in BRCA1/2, ATM or one of the other genes involved in the HRR pathway. The trial design included 2 cohorts; Cohort A included patients with BRCA1,2 or ATM and Cohort 2 included patients with 12 other HRR genes. (more…)
Author Interviews, Dermatology / 25.06.2020

MedicalResearch.com Interview with: Dr. Jonathan L. Silverberg MD PhD MPH Assistant Professor in Dermatology Medical Social Sciences and Preventive Medicine Northwestern, Chicago, Illinois MedicalResearch.com: What is the background for this study? Response: Topical anti-inflammatory therapy is often inadequate to achieve disease control in patients with moderate-to-severe atopic dermatitis (AD), and systemic therapy is often warranted. Tralokinumab is a fully human immunoglobulin G4 monoclonal antibody that specifically binds to the IL-13 cytokine with high affinity and inhibits downstream IL-13 pro-inflammatory signaling. Tralokinumab was previously studied as a monotherapy in moderate-severe AD in the ECZTRA1 and ECZTRA2 studies. In this Phase 3 randomized controlled study, ECZTRA3, tralokinumab was studies in combination with topical corticosteroids compared to placebo with topical corticosteroids. The use of topical anti-inflammatory therapy is more akin to the way in which systemic and biologic therapies are typically used in the real-world. (more…)
Author Interviews, C. difficile, Pediatrics / 07.08.2019

MedicalResearch.com Interview with: Larry K. Kociolek, MD MSCI Attending Physician, Division of Infectious Diseases, Associate Medical Director of Infection Prevention and Control, Ann & Robert H. Lurie Children’s Hospital of Chicago Assistant Professor of Pediatrics Northwestern University Feinberg School of Medicine  MedicalResearch.com: What is the background for this study? What are the main findings? Response: Clostridioides (Clostridium) difficile colonization is very common among infants, yet infants almost never develop symptoms of infection. In adults, it is known that immunity against the toxins that C. difficile produces protect against C. difficile infection (CDI). Our goal was to determine whether or not infants who become colonized with C. difficile develop an immune response against these toxins. We collected stool from healthy infants at multiple time points during the first year of life to determine whether or not they became colonized with C. difficile. Then at 9-12 months old, we collected blood to see if we can identify antibodies in their blood that protect against these toxins. We discovered that colonization with C. difficile during infancy was strongly associated with the development of antibodies. These antibodies were able to protect against the harmful effects of these toxins in a laboratory cell culture model. (more…)
Author Interviews, Hepatitis - Liver Disease, JAMA, OBGYNE, USPSTF / 24.07.2019

MedicalResearch.com Interview with: Melissa Simon, M.D., M.P.H.  George H. Gardner Professor of Clinical Gynecology Vice Chair of Clinical Research, Department of Obstetrics and Gynecology Professor of Preventive Medicine and Medical Social Sciences Northwestern University Feinberg School of Medicine MedicalResearch.com: What is the background for this study? What are the main findings? Response: Hepatitis B is a viral infection of the liver caused by the hepatitis B virus, or HBV. HBV causes liver disease, which can be either a mild, short-term illness, or a serious, lifelong issue. The U.S. Preventive Services Task Force has reaffirmed its 2009 recommendation that clinicians screen all pregnant people for HBV at their first prenatal visit. This is an A recommendation. (more…)
Author Interviews, Heart Disease, JAMA, Lipids / 02.04.2019

MedicalResearch.com Interview with: Victor Wenze Zhong, Ph.D. Postdoctoral fellow Department of Preventive Medicine Feinberg School of Medicine Northwestern University Chicago, IL 60611  MedicalResearch.com: What is the background for this study? Response: Dietary cholesterol is a common nutrient in human diet. Eggs, specially egg yolks, are the single richest source of dietary cholesterol among all commonly consumed foods. The associations between dietary cholesterol consumption and cardiovascular disease and mortality remain controversial despite decades of research. Eating less than 300 mg of dietary cholesterol per day was the guideline recommendation before 2015. However, the most recent 2015-2020 Dietary Guidelines for Americans no longer include a daily consumption limit for dietary cholesterol and recommend weekly egg consumption as part of the healthy US-style eating pattern. Whether these recommendations are appropriate have been intensely debated. (more…)
Author Interviews, Depression, Dermatology / 24.03.2019

MedicalResearch.com Interview with: Dr. Jonathan L. Silverberg MD PhD MPH Assistant Professor in Dermatology Medical Social Sciences and Preventive Medicine Northwestern, Chicago, Illinois MedicalResearch.com: What is the background for this study? What are the main findings?  Response: Atopic Dermatitis is characterized by chronic and often severe and debilitating itch, skin pain, sleep disturbances, skin lesions and multiple comorbid health conditions. The signs, symptoms and comorbidities of atopic dermatitis can lead to significant psychosocial distress and mental health burden We performed a cross-sectional, population-based study of 2893 US adults. We found that adults with atopic dermatitis had more severe symptoms scores for anxiety and depression (Hospital Anxiety and Depression anxiety). Adults with atopic dermatitis also had higher prevalences of anxiety and depression. Mean symptom scores and prevalences of anxiety and depression were even higher in adults with moderate and severe atopic dermatitis compared to those with mild atopic dermatitis. All respondents with severe PO-SCORAD, POEM and PO-SCORAD-itch scores had elevated anxiety and depression scores. Many adults with atopic dermatitis that had elevated anxiety and depression scores reported no diagnosis of anxiety or depression.  (more…)